Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?

World Journal of Gastroenterology

Volumn 23, Issue 35, 2017, Pages 6385-6402

  Vasudevan, Abhinav ^a,b   Gibson, Peter R ^b   Van Langenberg, Daniel R ^a,b  

^a BOX HILL HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Biologics; Clinical pharmacology; Crohn's disease; Inflammatory bowel disease; Nutrition; Thiopurines; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ALLOPURINOL; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CALCINEURIN INHIBITOR; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; VEDOLIZUMAB; GASTROINTESTINAL AGENT;

AGE; CROHN DISEASE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; ENTERIC FEEDING; HUMAN; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SMOKING; TREATMENT INDICATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTERAL NUTRITION; GASTROINTESTINAL AGENTS; HUMANS; PATIENT EDUCATION AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 85030107717     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i35.6385     Document Type: Review

References (157)

1. Markowitz J. Early inflammatory bowel disease: different treatment response to specific or all medications? Dig Dis 2009; 27: 358-365 [PMID: 19786765 DOI: 10.1159/000228574]
2. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d' Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-818 [PMID: 2179031 DOI: 10.10 16/0016-5085(90)90002-I]
3. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut 1994; 35: 231-235 [PMID: 7508411 DOI: 10.1136/gut.35.2.231]
4. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014; 63: 88-95 [PMID: 23974954 DOI: 10.1136/gutjnl-2013-304984]
5. Jharap B, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther 2015; 42: 1082-1092 [PMID: 26381802 DOI: 10.1111/apt.13387]
6. Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A, Horvath G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovasz BD, Vegh Z, Golovics PA, Szathmari M, Papp M, Lakatos PL; Hungarian IBD Study Group. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011; 34: 911-922 [PMID: 21883326 DOI: 10.1111/j.1365-2036.2011.04827.x]
7. Turner D, Griffiths AM, Veerman G, Johanns J, Damaraju L, Blank M, Hyams J. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol 2013; 11: 1460-1465 [PMID: 23672831 DOI: 10.1016/j.cgh.2013.04.049]
8. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol 2016; 14: 348-354. e17 [PMID: 26071941 DOI: 10.1016/j.cgh.2015.06.001]
9. Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 4: CD000543 [PMID: 27101467 DOI: 10.1002/14651858.CD000543.pub4]
10. Ford AC, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 617-629 [PMID: 21407190 DOI: 10.1038/ajg.2011.71]
11. Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2016; 7: CD008870 [PMID: 27372735 DOI: 10.1002/14651858.CD008870.pub2]
12. Miglioli MB, Brunetti G. Delayed release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterol Hepatol 1990; 2: 229-234
13. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Oncedaily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75; quiz 432-433 [PMID: 17241860 DOI: 10.1053/j.gastro.2006.10.011]
14. Baron JH, Connell AM, Lennard-jones JE, Jones FA. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; 1: 1094-1096 [PMID: 13865153]
15. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CW, Jones FA. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1: 217-222 [PMID: 13760840 DOI: 10.1136/gut.1.3.217]
16. Selby WS, Barr GD, Ireland A, Mason CH, Jewell DP. Olsalazine in active ulcerative colitis. Br Med J (Clin Res Ed) 1985; 291: 1373-1375 [PMID: 3933675 DOI: 10.1136/bmj.291.6506.1373]
17. Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998; 114: 15-22 [PMID: 9428213 DOI: 10.1016/S0016-5085(98)70627-4]
18. Oliva-Hemker M, Hutfless S, Al Kazzi ES, Lerer T, Mack D, LeLeiko N, Griffiths A, Cabrera J, Otley A, Rick J, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Carvalho R, Keljo D, Pfefferkorn M, Faubion W Jr, Kappelman M, Sudel B, Schaefer ME, Markowitz J, Hyams JS. Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. J Pediatr 2015; 167: 527-532.e1-3 [PMID: 25982142 DOI: 10.1016/j.jpeds.2015.04.045]
19. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383-1389 [PMID: 2896139 DOI: 10.1016/0016-5085(88)90677-4]
20. Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 1398-1407 [PMID: 12094857 DOI: 10.1111/j.1572-0241.2002.05781.x]
21. Orchard TR, van der Geest SA, Travis SP. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis-new light on a familiar question. Aliment Pharmacol Ther 2011; 33: 1028-1035 [PMID: 21385195 DOI: 10.1111/j.1365-2036.2011.04620.x]
22. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald R. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 36-43 [PMID: 15017515 DOI: 10.1053/jcgh.2003.50006]
23. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T, Targan S, Fleishman C, Wiita B. A doubleblind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-1871 [PMID: 9382054]
24. Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis-additional results from two controlled studies. Aliment Pharmacol Ther 2011; 34: 747-756 [PMID: 21848857 DOI: 10.1111/j.1365-2036.2011.04800.x]
25. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis 1998; 4: 79-83 [PMID: 9589293]
26. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-987 [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048]
27. Shepherd HA, Barr GD, Jewell DP. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease. J Clin Gastroenterol 1986; 8: 154-159 [PMID: 3745849 DOI: 10.1097/00 004836-198604000-00010]
28. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962; 2: 1708-1711 [PMID: 13994348 DOI: 10.1136/bmj.2.5321.1708]
29. Hawthorne AB, Record CO, Holdsworth CD, Giaffer MH, Burke DA, Keech ML, Hawkey CJ. Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. Gut 1993; 34: 125-128 [PMID: 8432442 DOI: 10.1136/gut.34.1.125]
30. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 2: 441-443 [PMID: 13865152]
31. Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, Morgenstern EH, Rubin SD, Sacknoff AG, Gleim GM. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized doubleblind study and follow-up. Inflamm Bowel Dis 1998; 4: 177-181 [PMID: 9741018 DOI: 10.1097/00054725-199808000-00001]
32. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-1070 [PMID: 4135487 DOI: 10.1016/S0140-6736(74)90552-2]
33. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-1088 [PMID: 82099 DOI: 10.1016/S0140-6736(78)91816-0]
34. Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-1013 [PMID: 3930339 DOI: 10.1016/0016-5085(85)90201-X]
35. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910 [PMID: 8984031 DOI: 10.1136/gut.38.6.905]
36. Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Wittmann T. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. J Gastrointestin Liver Dis 2011; 20: 359-363 [PMID: 22187700]
37. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A; Budesonide CIR United States Study Group. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002; 97: 1748-1754 [PMID: 12135030 DOI: 10.1111/j.1572-0241.2002.05835.x]
38. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bär U, Weber A, Gierend M, Ewe K, Schölmerich J. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996; 8: 905-909 [PMID: 8889459]
39. Tursi A, Giorgetti GM, Brandimarte G, Elisei W, Aiello F. Beclomethasone dipropionate for the treatment of mild-tomoderate Crohn's disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006; 12: PI29-PI32 [PMID: 16733496]
40. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339: 370-374 [PMID: 9691103 DOI: 10.1056/NEJM199808063390603]
41. Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED 2nd. Once-daily budesonide MMX ® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218-1226.e1-2 [PMID: 22892337 DOI: 10.1053/j.gastro.2012.08.003]
42. D'Haens GR, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Binelli D, Di Stefano AF, Marteau P. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extendedrelease tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010; 4: 153-160 [PMID: 21122499 DOI: 10.1016/j.crohns.2009.09.007]
43. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5: V1-V16 [PMID: 15306569 DOI: 10.1136/gut.2004.043372]
44. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002]
45. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469-3477 [PMID: 11151879 DOI: 10.1111/j.1572-0241.2000.03363.x]
46. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035 [PMID: 9321530 DOI: 10.1056/NEJM199710093371502]
47. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]
48. Nikolaus S, Raedler A, Kühbacker T, Sfikas N, Fölsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000; 356: 1475-1479 [PMID: 11081530 DOI: 10.1016/S0140-6736(00)02871-3]
49. Tursi A, Elisei W, Giorgetti GM, Penna A, Picchio M, Brandimarte G. factors influencing mucosal healing in Crohn's disease during infliximab treatment. Hepatogastroenterology 2013; 60: 1041-1046 [PMID: 23803367 DOI: 10.5754/hge11514]
50. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]
51. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-88 [PMID: 11383595 DOI: 10.1097/000547 25-200105000-00001]
52. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050516]
53. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M; Groupe d' Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915 [PMID: 23063316 DOI: 10.1016/S0140-6736(12)61084-8]
54. Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2016; 14: 543-549 [PMID: 26681486 DOI: 10.1016/j.cgh.2015.11.014]
55. Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, Mulcahy HE, Cullen G, Doherty GA. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-335.e1 [PMID: 25086187 DOI: 10.1016/j.cgh.2014.07.041]
56. Austin Health. Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis (PREDICT-UC). Bethesda (MD): National Library of Medicine (US). Cited 2016-12-20. Available from: URL: https://clinicaltrials.gov/show/NCT02770040
57. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591 [PMID: 16472588 DOI: 10.1053/j.gastro.2005.11.030]
58. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn' s disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-1111.e2 [PMID: 22326435 DOI: 10.1053/j.gastro.2012.01.035]
59. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787 [PMID: 21209123 DOI: 10.1136/gut.2010.221127]
60. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D' Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265.e1-e3 [PMID: 22062358 DOI: 10.1053/j.gastro.2011.10.032]
61. Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011; 9: 670-678.e3 [PMID: 21642014 DOI: 10.1016/j.cgh.2011.04.031]
62. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A; CDP870 Crohn's Disease Study Group. A randomized, placebocontrolled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-818 [PMID: 16143120 DOI: 10.1053/j.gastro.2005.06.064]
63. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238 [PMID: 17634458 DOI: 10.1056/NEJMoa067594]
64. Hébuterne X, Lémann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, D'Haens G, Mitchev K, Ernault É, Vermeire S, Brixi-Benmansour H, Moreels TG, Mary JY, Marteau P, Colombel JF. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013; 62: 201-208 [PMID: 22525883 DOI: 10.1136/gutjnl-2012-302262]
65. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUITSC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95; quiz e14-15 [PMID: 23735746 DOI: 10.1053/j.gastro.2013.05.048]
66. Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22: 10432-10439 [PMID: 28058024 DOI: 10.3748/wjg.v22. i47.10432]
67. Castro-Laria L, Argüelles-Arias F, García-Sánchez V, Benítez JM, Fernández-Pérez R, Trapero-Fernández AM, Gallardo-Sánchez F, Pallarés-Manrique H, Gómez-García M, Cabello-Tapia MJ, Talavera-Fabuel A, Bejarano-García A, Leo-Carnerero E, Hernández-Martínez Á, Caunedo-Álvarez Á, Herrerías-Gutiérrez JM. Initial experience with golimumab in clinical practice for ulcerative colitis. Rev Esp Enferm Dig 2016; 108: 129-132 [PMID: 26786341 DOI: 10.17235/reed.2016.4068/2015]
68. Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, Reinisch W, Gibson PR, Sandborn WJ; PURSUIT-IV study group. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther 2015; 42: 504-514 [PMID: 26119226 DOI: 10.1111/apt.13291]
69. Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther 2015; 42: 330-342 [PMID: 26031921 DOI: 10.1111/apt.13251]
70. Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis 2017; 11: 35-46 [PMID: 27440869 DOI: 10.1093/ecco-jcc/jjw133]
71. Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D' Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 423-431.e1 [PMID: 24184736 DOI: 10.1016/j.cgh.2013.10.025]
72. Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naitov Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T. 854 Comparison of Adalimumab Monotherapy and a Combination With Azathioprine for Patients With Crohn's Disease: A Prospective, Multicenter, Open-Labeled Clinical Trial (DIAMOND Study). Gastroenterology 2016; 150: S182 [DOI: 10.1016/S0016-5085(16)30697-7]
73. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-721 [PMID: 23964933 DOI: 10.1056/NEJMoa1215739]
74. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618-627. e3 [PMID: 24859203 DOI: 10.1053/j.gastro.2014.05.008]
75. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol 2016; 111: 1147-1155 [PMID: 27296941 DOI: 10.1038/ajg.2016.236]
76. Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, Gutierrez AM, Ciorba MA. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. J Crohns Colitis 2016; 10: 402-409 [PMID: 26681763 DOI: 10.1093/eccojcc/jjv226]
77. Bryant RV, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis 2015; 9: 356-366 [PMID: 25687206 DOI: 10.1093/ecco-jcc/jjv033]
78. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]
79. Moon W, Loftus EV Jr. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2016; 43: 863-883 [PMID: 26876431 DOI: 10.1111/apt.13559]
80. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH Jr. Lack of effect of intravenous administration on time to respond to azathioprine for steroidtreated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 527-535 [PMID: 10464128 DOI: 10.1016/S0016-5085(99)70445-2]
81. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 944-947 [PMID: 4107900 DOI: 10.1016/S0140-6736(71)90268-6]
82. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A longterm, randomized, double-blind study. N Engl J Med 1980; 302: 981-987 [PMID: 6102739 DOI: 10.1056/NEJM198005013021801]
83. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003; 35: 619-627 [PMID: 14563183 DOI: 10.1016/S1590-8658(03)00372-4]
84. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009; 15: 375-382 [PMID: 19009634 DOI: 10.1002/ibd.20777]
85. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284: 1291-1292 [PMID: 6803944 DOI: 10.1136/bmj.284.6325.1291]
86. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-630 [PMID: 4441827 DOI: 10.1136/bmj.4.5945.627]
87. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53 [PMID: 15972298 DOI: 10.1136/gut.2005.068809]
88. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96-99 [PMID: 1097295]
89. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187-208 [PMID: 17328579 DOI: 10.2165/00003088-200746030-00001]
90. Sandborn WJ. Ra t iona l dos ing of a z a thiopr ine and 6-mercaptopurine. Gut 2001; 48: 591-592 [PMID: 11302950 DOI: 10.1136/gut.48.5.591]
91. Sandborn WJ, Van O EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995; 109: 1808-1817 [PMID: 7498645 DOI: 10.1016/0016-5085(95)90747-5]
92. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005; 100: 2239-2247 [PMID: 16181376 DOI: 10.1111/j.1572-0241.2005.41900.x]
93. Reinshagen M, Schütz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Kruis W, Oellerich M, von Ahsen N. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007; 53: 1306-1314 [PMID: 17495015 DOI: 10.1373/clinchem.2007.086215]
94. Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, Sandler RS, Hanauer SB. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther 2014; 39: 163-175 [PMID: 24237037 DOI: 10.1111/apt.12555]
95. Moreau AC, Paul S, Del Tedesco E, Rinaudo-Gaujous M, Boukhadra N, Genin C, Peyrin-Biroulet L, Roblin X. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis 2014; 20: 464-471 [PMID: 24418904 DOI: 10.1097/01. MIB.0000439068.71126.00]
96. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713 [PMID: 10734022 DOI: 10.1016/S0016-5085(00)70140-5]
97. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-646 [PMID: 11302961 DOI: 10.1136/gut.48.5.642]
98. Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1301-1307 [PMID: 20812329 DOI: 10.1002/ibd.21458]
99. Kennedy NA, Asser TL, Mountifield RE, Doogue MP, Andrews JM, Bampton PA. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Intern Med J 2013; 43: 278-286 [PMID: 22946880 DOI: 10.1111/j.1445-5994.2012.02936.x]
100. Smith M, Blaker P, Patel C, Marinaki A, Arenas M, Escuredo E, Anderson S, Irving P, Sanderson J. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 2013; 67: 161-169 [PMID: 23253089 DOI: 10.1111/ijcp.12039]
101. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D, Hanauer SB. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22: 441-446 [PMID: 16128682 DOI: 10.1111/j.1365-2036.2005.02583.x]
102. Rahhal RM, Bishop WP. Initial clinical experience with allopurinolthiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1678-1682 [PMID: 18521913 DOI: 10.1002/ibd.20522]
103. Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 2009; 3: 162-167 [PMID: 21172265 DOI: 10.1016/j.crohns.2009.02.003]
104. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-647 [PMID: 20015102 DOI: 10.1111/j.1365-2036.2009.04221.x]
105. Pavlidis P, Stamoulos P, Abdulrehman A, Kerr P, Bull C, Duley J, Ansari A. Long-term Safety and Efficacy of Lowdose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study. Inflamm Bowel Dis 2016; 22: 1639-1646 [PMID: 27271488 DOI: 10.1097/MIB.0000000000000827]
106. Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res 2015; 13: 193-207 [PMID: 26130993 DOI: 10.5217/ir.2015.13.3.193]
107. Yip JS, Woodward M, Abreu MT, Sparrow MP. How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis 2008; 14: 514-518 [PMID: 18088072 DOI: 10.1002/ibd.20345]
108. Kiszka-Kanowitz M, Theede K, Mertz-Nielsen A. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease. Scand J Gastroenterol 2016; 51: 1470-1475 [PMID: 27686002 DOI: 10.1080/00365521.2016.1216 589]
109. Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D; European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Gastroenterology 2016; 150: 380-388.e4 [PMID: 26632520 DOI: 10.1053/j.gastro.2015.10.050]
110. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-356 [PMID: 2492786 DOI: 10.7326/0003-481 9-110-5-353]
111. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001; 15: 35-44 [PMID: 11136276 DOI: 10.1046/j.1365-2036.2001.00908.x]
112. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Bardan E, Villa Y, Gilat T. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-1421 [PMID: 8613046 DOI: 10.1053/gast.1996.v110.pm8613046]
113. Islam MS, Haq SA, Islam MN, Azad AK, Islam MA, Barua R, Hasan MM, Mahmood M, Safiuddin M, Rahman MM, Osmany MF, Bari N, Rumki RS, Rashid FB. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Med J 2013; 22: 483-488 [PMID: 23982537]
114. Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ. A randomized doseresponse and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1597-1604 [PMID: 10594394 DOI: 10.1046/j.1365-2036.1999.00667.x]
115. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis 1999; 5: 167-173 [PMID: 10453372 DOI: 10.1097/00054725-199908000-00004]
116. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2766-2774 [PMID: 15457444 DOI: 10.1002/art.20460]
117. Fischer M, Siva S, Cook GK, Jones DR, Fadda HM. Methotrexate Polyglutamate Monitoring in Patients With Crohn's Disease. Clin Pharmacol Drug Dev 2017; 6: 240-245 [PMID: 27274011 DOI: 10.1002/cpdd.279]
118. Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit 2007; 29: 619-625 [PMID: 17898653 DOI: 10.1097/FTD.0b013e31811f39bb]
119. Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol 2014; 41: 1049-1060 [PMID: 24737913 DOI: 10.3899/jrheum.130738]
120. McSharry K, Dalzell AM, Leiper K, El-Matary W. Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther 2011; 34: 1282-1294 [PMID: 21999607 DOI: 10.1111/j.1365-2036.2011.04873.x]
121. McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005; (2): CD000297 [PMID: 15846602 DOI: 10.1002/14651858.CD000297.pub2]
122. Ogata H, Kato J, Hirai F, Hida N, Matsui T, Matsumoto T, Koyanagi K, Hibi T. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18: 803-808 [PMID: 21887732 DOI: 10.1002/ibd.21853]
123. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-1262 [PMID: 16484504 DOI: 10.1136/gut.2005.081794]
124. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroidrefractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-1056 [PMID: 16573777 DOI: 10.1111/j.1572-0241.2006.00524.x]
125. Tamaki H, Nakase H, Matsuura M, Inoue S, Mikami S, Ueno S, Uza N, Kitamura H, Kasahara K, Chiba T. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease. J Gastroenterol 2008; 43: 774-779 [PMID: 18958546 DOI: 10.1007/s00535-008-2229-y]
126. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. Randomized, doubleblind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031 [PMID: 14517785 DOI: 10.1016/S0016-5085(03)01214-9]
127. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329 [PMID: 11313301 DOI: 10.1053/gast.2001.23983]
128. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 317-324 [PMID: 12479646 DOI: 10.1097/00054725-2002 09000-00002]
129. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 4: 276-279 [PMID: 9836079]
130. Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn's disease: a review. World J Gastroenterol 2013; 19: 7652-7660 [PMID: 24282355 DOI: 10.3748/wjg.v19.i43.7652]
131. Giaffer MH, North G, Holdsworth CD. Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease. Lancet 1990; 335: 816-819 [PMID: 1969560 DOI: 10.101 6/0140-6736(90)90936-EY]
132. Gassull MA, Fernández-Bañares F, Cabré E, Papo M, Giaffer MH, Sánchez-Lombraña JL, Richart C, Malchow H, González-Huix F, Esteve M; Eurpoean Group on Enteral Nutrition in Crohn's Disease. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut 2002; 51: 164-168 [PMID: 12117873 DOI: 10.1136/gut.51.2.164]
133. Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K, Hibi T, Iwao Y, Munakata A, Fukuda S, Matsumoto T, Oshitani N, Hiwatashi N, Oriuchi T, Kitahora T, Utsunomiya T, Saitoh Y, Suzuki Y, Nakajima M. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol 2003; 15: 151-157 [PMID: 12560759 DOI: 10.1097/01.meg.0000049987.68425.b3]
134. Mansfield JC, Giaffer MH, Holdsworth CD. Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn' s disease. Gut 1995; 36: 60-66 [PMID: 7890238 DOI: 10.1136/gut.36.1.60]
135. Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 2000; 95: 735-739 [PMID: 10710067 DOI: 10.1111/j.1572-0241.2000.01527.x]
136. Rigaud D, Cosnes J, Le Quintrec Y, René E, Gendre JP, Mignon M. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut 1991; 32: 1492-1497 [PMID: 1773955 DOI: 10.1136/gut.32.12.1492]
137. Middleton SJ, Rucker JT, Kirby GA, Riordan AM, Hunter JO. Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease. Clin Nutr 1995; 14: 229-236 [PMID: 16843936 DOI: 10.1016/S0261-5614(95)80004-2]
138. González-Huix F, de León R, Fernández-Bañares F, Esteve M, Cabré E, Acero D, Abad-Lacruz A, Figa M, Guilera M, Planas R. Polymeric enteral diets as primary treatment of active Crohn' s disease: a prospective steroid controlled trial. Gut 1993; 34: 778-782 [PMID: 8314510 DOI: 10.1136/gut.34.6.778]
139. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis 2005; 11: 580-588 [PMID: 15905706 DOI: 10.1097/01.MIB.0000161307.58327.96]
140. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, Donnet-Hughes A, MacDonald TT, Walker-Smith JA. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14: 281-289 [PMID: 10735920 DOI: 10.1046/j.1365-2036.2000.00707.x]
141. Juneja M, Schwartz M, El Mourabet M, Regueiro M, Harrison J, Barrie AM, Swoger JM, Baidoo L, Saul MI, Binion DG. W1276 W1276 Patterns of Medical Treatment and Polypharmacy in Geriatric Crohn's Disease. Gastroenterology 2010; 138: S-689 [DOI: 10.1016/S0016-5085(10)63167-8]
142. Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol 2011; 106: 1889-1897 [PMID: 21862997 DOI: 10.1038/ajg.2011.271]
143. Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther 2015; 42: 441-451 [PMID: 26104047 DOI: 10.1111/apt.13294]
144. Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2118-2124 [PMID: 23863401 DOI: 10.1097/MIB.0b013e31829cf401]
145. Bultman E, de Haar C, van Liere-Baron A, Verhoog H, West RL, Kuipers EJ, Zelinkova Z, van der Woude CJ. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012; 35: 335-341 [PMID: 22191671 DOI: 10.1111/j.1365-2036.2011.04946.x]
146. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-1898 [PMID: 3569765 DOI: 10.1016/0016-5085(87)90621-4]
147. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925 [PMID: 16267322 DOI: 10.1056/NEJMoa043335]
148. Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, Pruitt RE, Jacobs WH, Lo SK, Targan SR, Cerda JJ. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991; 115: 350-355 [PMID: 1863024 DOI: 10.7326/0003-4819-115-5-350]
149. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved longterm clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201 [PMID: 21723220 DOI: 10.1053/j.gastro.2011.06.054]
150. Llaó J, Naves JE, Ruiz-Cerulla A, Marín L, Mañosa M, Rodríguez-Alonso L, Cabré E, Garcia-Planella E, Guardiola J, Domènech E. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. J Crohns Colitis 2014; 8: 1523-1528 [PMID: 25066954 DOI: 10.1016/j.crohns.2014.06.010]
151. Shih DQ, Nguyen M, Zheng L, Ibanez P, Mei L, Kwan LY, Bradford K, Ting C, Targan SR, Vasiliauskas EA. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012; 36: 449-458 [PMID: 22784257 DOI: 10.1111/j.1365-2036.2012.05206.x]
152. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-1632 [PMID: 10833208 DOI: 10.1056/NEJM200006013422202]
153. Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Böcker U, Böhm S, Büning C, Duchmann R, Gerken G, Herfarth H, Lügering N, Kruis W, Reinshagen M, Schmidt J, Stallmach A, Stein J, Sturm A, Galle PR, Hommes DW, D'Haens G, Rutgeerts P, Neurath MF. Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. Dig Dis Sci 2010; 55: 1066-1078 [PMID: 19513841 DOI: 10.1007/s10620-009-0846-9]
154. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-1457 [PMID: 12823146 DOI: 10.1046/j.1365-2036.2003.01574.x]
155. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65 [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041]
156. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators. Increased response and remission rates in short-duration Crohn' s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010; 105: 1574-1582 [PMID: 20234346 DOI: 10.1038/ajg.2010.78]
157. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667 [PMID: 18295023 DOI: 10.1016/S0140-6736(08)60304-9]